Browsing Tag
Radiopharm Theranostics
5 posts
A small imaging trial could reshape how brain metastases are detected and Radiopharm Theranostics is betting on it (ASX: RAD)
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Discover the strategic and market implications.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.
Radiopharm Theranostics begins third-cohort enrolment in Phase 1 177Lu-RAD204 trial targeting PD-L1 tumours
Find out how Radiopharm Theranostics is advancing 177Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
Radiopharm Theranostics’ 68Ga-RAD 301 shows promise in pancreatic cancer imaging
Radiopharm Theranostics, a clinical-stage biopharmaceutical company, has announced compelling results from a study examining the effectiveness of 68Ga-Trivehexin…